◆英語タイトル:vTv Therapeutics Inc (VTVT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013235
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
vTv Therapeutics Inc (vTv), formerly TransTech Inc is a clinical stage pharmaceutical company that discovers, develops and commercializes small molecule drug candidates. The company’s pipeline products include azeliragon, TTP399, TTP273, HPP593, HPP737, HPP971 and hexokinase II inhibitors. Its products are used for treatment of central nervous system disorders, metabolic disorders, inflammatory diseases and cancer. vTv’s azeliragon (TTP488), developed to treat Alzheimer’s disease and is in Phase III clinical trials. The company utilizes its own drug discovery TTP translational technology, which includes three modules such as TTPredict, TTPSpace and TTPScreen for discovering and developing therapeutics for diseases. It collaborates with other pharmaceutical companies to discover and develop small molecule therapeutics to treat diseases. vTv is headquartered in High Point, North Carolina, the US.
vTv Therapeutics Inc (VTVT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
vTv Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
vTv Therapeutics Enters into Agreement with Juvenile Diabetes Research Foundation 10
Licensing Agreements 11
vTv Therapeutics Enters into Licensing Agreement with Columbia University 11
Calithera Biosciences Enters into Licensing Agreement with TransTech Pharma and High Point Pharma for Hexokinase II Inhibitor Program 12
Equity Offering 13
vTv Therapeutics Raises USD117.2 Million in IPO 13
vTv Therapeutics Inc – Key Competitors 14
vTv Therapeutics Inc – Key Employees 15
vTv Therapeutics Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Financial Announcements 17
Nov 01, 2017: vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results 17
Aug 02, 2017: vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results 19
May 03, 2017: vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results 20
Feb 27, 2017: vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights 21
Nov 02, 2016: vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights 23
Aug 16, 2016: vTv Therapeutics: Announced Second Quarter 2016 Financial Results 24
May 12, 2016: vTv Therapeutics Reports First Quarter Financial and Operational Results 26
Mar 01, 2016: vTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights 28
Clinical Trials 30
Oct 03, 2016: vTv Therapeutics to Present at Neuro Advance Boston 30
Sep 07, 2016: vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease 31
Sep 02, 2016: vTv Therapeutics to Present at the International Psychogeriatric Association International Congress 32
Jul 27, 2016: vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference 33
Jul 14, 2016: vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference 34
Feb 22, 2016: vTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273 35
Jan 21, 2016: vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
vTv Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
vTv Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
vTv Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
vTv Therapeutics Enters into Agreement with Juvenile Diabetes Research Foundation 10
vTv Therapeutics Enters into Licensing Agreement with Columbia University 11
Calithera Biosciences Enters into Licensing Agreement with TransTech Pharma and High Point Pharma for Hexokinase II Inhibitor Program 12
vTv Therapeutics Raises USD117.2 Million in IPO 13
vTv Therapeutics Inc, Key Competitors 14
vTv Therapeutics Inc, Key Employees 15
vTv Therapeutics Inc, Subsidiaries 16